Imiquimod and resiquimod in a mouse model: Adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

Vaccine

Volumn 22, Issue 13-14, 2004, Pages 1799-1809

  Thomsen, Lindy L ^a   Topley, Peter ^a   Daly, Maria G ^a   Brett, Sara J ^a   Tite, John P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adjuvant; DNA vaccination; Imiquimod; Resiquimod; T cells; TLR7

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 4; PLASMID DNA; RESIQUIMOD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE DELIVERY SYSTEM; GENE GUN; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIGENS, CD11; BIOLISTICS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; IMIDAZOLES; IMMUNIZATION; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LYMPH NODES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSPHERES; OVALBUMIN; PLASMIDS; TH1 CELLS; VACCINES, DNA;

EID: 1842479742     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.09.052     Document Type: Article

References (29)

1. Lewis P.J., Babiuk L.A. DNA vaccines: a review. Adv. Virus Res. 54:1999;129-188.
2. Reyes-Sandoval A., Ertl H.C. DNA vaccines. Curr. Mol. Med. 1(2):2001;217-243.
3. Lui M.A. DNA vaccines: a review. J. Int. Med. 253:2003;402-410.
4. Scheerlinck J.-P.Y. Genetic adjuvants for DNA vaccines. Vaccine. 19:2001;2647-2656.
5. Dockrell D.H., Kinghorn G.R. Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob. Chemother. 48:2001;751-755.
6. Stanley M.A. Imiquimod and the imidazoquinolines: mechanism of action and therapeutic potential. Clin. Dermatol. 27:2002;571-577.
7. Gibson S.J., Imbertson L.M., Wagner T.L., Testerman T.L., Reiter M.J., Miller R.L.et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J. Interferon Cytokine Res. 15:1995;537-545.
8. Testerman T.L., Gerster J.F., Imbertson L.M., Reiter M.J., Miller R.L., Gibson S.J.et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukocyte Biol. 58:1995;365-372.
9. Imbertson L.M., Beaurline J.M., Couture A.M., Gibson S.J., Smith R.M.A., Miller R.L.et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest. Dermatol. 110:1998;734-739.
10. Miller R.L., Gerster J.F., Owens M.L., Slade H.B., Tomai M.A. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 21:1999;1-14.
11. Bernstein D.I., Harrison C.J., Tepe E.R., Shahwan A., Miller R.L. Effect of imiquimod as an adjuvant for immuntherapy of genital HSV in guinea-pigs. Vaccine. 13(1):1995;72-76.
12. Borden E.C., Sidky Y.A., Weeks C.E. Mechanisms of anti-tumor action of the interferon inducer R-837. Proc. Am. Assoc. Cancer Res. 32:1991;258.
13. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K.et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2):2002;196-200.
14. + T cells following particle-mediated DNA vaccination: implications for the study of immunomodulation. Vaccine. 19:2001;1678-1687.
15. Thomsen L.L., Young M., Topley P., Kaur H., Ellis J. DNA immunisation by gene gun: coexpression with GM-CSF enhances humoral and cellular responses to plasmid encoding ovalbumin. Immunology. 95:1998;108.
16. Eisenbraun M.D., Fuller D.H., Haynes J.R. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. DNA Cell Biol. 12(9):1993;791-797.
17. Kono T., Kondo S., Pastore S., Shivji G.M., Tomai M.A., McKenzie R.C.et al. Effects of a novel topical immunomodulator, imiquimod, on keratinoctye cytokine gene expression. Lymphokine Cytokine Res. 13(2):1994;71-76.
18. Fujisawa H., Shivji G.M., Kondo S., Wang B., Tomai M.A., Miller R.L.et al. Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production. J. Interferon Cytokine Res. 16:1996;555-559.
19. Ahonen C.L., Gibson S.J., Smith R.M., Pederson L.K., Lindh J.M., Tomai M.A.et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell. Immunol. 197:1999;62-72.
20. Wagner T.L., Ahonen C.L., Couture A.M., Gibson S.J., Miller R.L., Smith R.M.et al. Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 191:1999;10-19.
21. Burns R.P., Ferbel B., Tomai M., Miller R., Gaspari A.A. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans cells. Clin. Immunol. 94(1):2000;13-23.
22. Bishop G.A., Ramirez L.M., Baccam M., Busch L.K., Pederson L.K., Tomai M.A. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell. Immunol. 208:2001;9-17.
23. Vasilakos J.P., Smith R.M.A., Gibson S.J., Lindh J.M., Pederson L.K., Reiter M.J.et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol. 204:2000;64-74.
24. Wagner T.L., Horton V.L., Carlson G.L., Myhre P.E., Gibson S.J., Imbertson L.M.et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine. 9(11):1997;837-845.
25. Sidky Y.A., Border E.C., Weeks C.E., Reiter M.J., Hatcher J.F., Bryan G.T. Inhibition of murine tumour growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 52:1992;3528-3533.
26. Reiter M.J., Testerman T.L., Miller R.L., Weeks C.E., Tomai M.A. Cytokine induction in mice by the immunomodulator imiquimod. J. Leukocyte Biol. 55:1994;234-240.
27. Goldstein D., Hertzog P., Tomkinson E., Couldwell D., McCarville S., Parrish S.et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J. Infect. Dis. 178:1998;858-861.
28. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H.et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3(6):2002;499.
29. Anderson K.V. Toll signaling pathways in the innate immune response. Curr. Opin. Immunol. 12:2000;13-19.